Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma

Hepatology

Volumn 49, Issue 5, 2009, Pages 1492-1502

  Ding, Fei Xiang ^a   Wang, Fang ^a   Lu, Yi Ming ^a   Li, Ka ^a   Wang, Kai Hui ^a   He, Xiao Wen ^a   Sun, Shu Han ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CORE PROTEIN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HEPATITIS B VIRUS X PROTEIN; HLA A2 ANTIGEN; LEUKOCYTE ANTIGEN; MULTIEPITOPE PEPTIDE LOADED VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; EPITOPE; HEPATITIS B VACCINE; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; SUBUNIT VACCINE; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ERYTHROCYTE COUNT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TRANSGENIC MOUSE; ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; CYTOTOXICITY; IMMUNOLOGY; LIVER TUMOR; METABOLISM; PROTEIN STABILITY; TUMOR CELL LINE; VACCINATION; VIROLOGY;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HEPATITIS B VACCINES; HLA-A ANTIGENS; HUMANS; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; PROTEIN STABILITY; TRANS-ACTIVATORS; VACCINATION; VACCINES, SUBUNIT; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 66149094633     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22816     Document Type: Article

References (43)

1. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15(Suppl):E25-E30.
2. Inchauspé G, Michel ML. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat 2007;14(Suppl 1):97-103.
3. Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001;19:1837-1848.
4. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:261-281.
5. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97:1655-1665.
6. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1997;94:8744-8749.
7. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320.
8. Cheng Z, Hu J, King J, Jay G, Campbell TC. Inhibition of hepatocellular carcinoma development in hepatitis B virus transfected mice by low dietary casein. HEPATOLOGY 1997;26:1351-1354.
9. Su Q, Schroder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. HEPATOLOGY 1998;27:1109-1120.
10. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1: 751-761.
11. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999;22:431-440.
12. Grgacic EV, Anderson DA. Virus-like particles: Passport to immune recognition. Methods 2006;40:60-65.
13. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007;18:537-545.
14. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A 2004;101:14646-14652.
15. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, et al. Identification and characterization of the immunodominant rat HER-2/ neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003;170:4273-4280.
16. Nielsen M, Lundegaard C, Lund O, Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005;57:33-41.
17. Grufman P, Sandberg JK, Wolpert EZ, Karre K. Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens. J Leukoc Biol 1999;66: 268-271.
18. He XW, Jiang L, Wang F, Xiao Z, Li J, Liu LS, et al. Augmented humoral and cellular immune responses of a hepatitis BDNA vaccine adsorbed onto cationic microparticles. J Control Release 2005;107:357-372.
19. Choi EM, Palmowski M, Chen J, Cerundolo V. The use of chimeric A2Kb tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice. J Immunol Methods 2002;268:35-41.
20. Wang B, Chen H, Jiang X, Zhang M, Wan T, Li N, et al. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 2004;104:200-206.
21. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, et al. T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein. J Immunol 2001;166:5300-5308.
22. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, LethéB, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003;171:4898-4904.
23. Chun E, Lee J, Cheong HS, Lee KY. Tumor eradication by hepatitis B virus X antigen-specific CD8+T cells in xenografted nude mice. J Immunol 2003;170:1183-1190.
24. Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, et al. ALK as a novel lymphoma-associated tumor antigen: Identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002;99: 2100-2106.
25. Gianfrani C, Troncone R, Mugione P, Cosentini E, De Pascale M, Faruolo C, et al. Celiac disease association with CD8+ T cell responses: identification of a novel gliadin-derived HLA-A2-restricted epitope. J Immunol 2003;170:2719-2726.
26. Jalili A, Ozaki S, Hara T, Shibata H, Hashimoto T, Abe M, et al. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood 2005; 106:3538-3545.
27. Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996;20: 102-110.
28. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-1365.
29. Furukawa S, Akbar SM, Hasebe A, Horiike N, Onji M. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: Evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo. Immunobiology 2004;209:551-557.
30. Armengol C, Tarafa G, Boix L, Solé M, Queralt R, Costa D, et al. Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res 2004;10:2150-2157.
31. Bertoletti A, Chisari FV, Penna A. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 1993;67:2376-2380.
32. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987;56:651-693.
33. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. HEPATOLOGY 2004;39:1683-1693.
34. Tralhao JG, Roudier J, Morosan S, Giannini C, Tu H, Goulenok C, et al. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: An alternative mechanism of HBx-related pathogenesis. Proc Natl Acad Sci U S A 2002;99:6991-6996.
35. Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 2005;105:3605-3614.
36. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001;166:5346-5355.
37. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;13:46-53.
38. Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006;7:173-178.
39. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005;73:3587-3597.
40. Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, et al. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: Evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol 2002;168:6189-6198.
41. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001;19:4652-4660.
42. Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999;162:3915-3925.
43. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-212.